You just read:

Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers

News provided by

Pharmacyclics, Inc.

May 28, 2015, 09:00 ET